In addition, Depression currently affects 264 million people globally and 20% of Americans ages 18+ in any given year
Current treatments for ASIB include hospitalization and/or anti-depressants – many with a black box warning as they can lead to increase in suicidal thoughts in certain populations.
Amyotrophic Lateral Sclerosis (ALS), or Lou Gehrig’s Disease
is a fatal (life expectancy of 10 to 20 years) neurodegenerative disease characterized by progressive muscle paralysis determined by the degeneration of neurons in the motor cortex brainstem and spinal cord,
has Orphan designation in the U.S. and the European Union,
has shown in in-vivo studies that treatment with oral trehalose:
delayed the progression of the disease thereby prolonging survival,
reduced skeletal muscle denervation,
reduced motor neuron loss and skeletal denervation,
improved autophagy flux and
decreased aggregation of SOD1 and SQSTM1/p62.
Spinocerebellar Ataxia (SCA)
is a serious adult-onset (begins between the ages of 20 and 50) neurodegenerative disease caused by degeneration of the cerebellum characterized by:
progressive unsteadiness of gait and stance,
impaired coordination of limb movements,
slurred speech and
abnormal eye movements
commonly affects individuals of Portuguese/Azorean descent,
has Orphan designation in the U.S. and the European Union and
has Fast Track designation in the U.S.
SCA type 3, also known as Machado-Joseph Disease (MJD):
is a progressive cerebellar ataxia and is known to cause progressively severe disability and often premature death.
Weekly infusions of SLS-005 were found to be generally safe and tolerated with no changes in safety
Patients remained stable during treatment with no significant change in SARA score over 6 months and the 6 patients who continued to receive treatment for 12 months had SARA scores that remained stable.
Trehalose improved symptoms in 61.5% of SCA patients